S&P 500
(0.38%) 5 037.26 points
Dow Jones
(0.44%) 38 068 points
Nasdaq
(0.73%) 15 719 points
Oil
(-0.28%) $78.78
Gas
(4.76%) $2.02
Gold
(0.04%) $2 311.90
Silver
(0.24%) $26.81
Platinum
(0.73%) $961.90
USD/EUR
(0.14%) $0.934
USD/NOK
(0.06%) $11.04
USD/GBP
(0.18%) $0.800
USD/RUB
(-1.37%) $91.98

Aktualne aktualizacje dla Keros Therapeutics Inc [KROS]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
Upcoming Earnings Alert

Quarter results today
(bmo 2024-05-02)

Expected move: +/- 8.49%

BUY
100.00%
return 19.70%
SELL
33.33%
return 10.33%
Ostatnio aktualizowano2 geg. 2024 @ 18:42

0.07% $ 57.76

SPRZEDAż 112053 min ago

@ $58.15

Wydano: 14 vas. 2024 @ 22:11


Zwrot: -0.67%


Poprzedni sygnał: vas. 13 - 16:30


Poprzedni sygnał: Kupno


Zwrot: 4.68 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:42):
Profile picture for Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need...

Stats
Dzisiejszy wolumen 77 807.00
Średni wolumen 361 314
Kapitalizacja rynkowa 2.08B
EPS $-1.340 ( 2024-03-01 )
Następna data zysków ( $-1.350 ) 2024-05-30
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -11.11
ATR14 $0.133 (0.23%)
Insider Trading
Date Person Action Amount type
2024-02-23 Seehra Jasbir Buy 125 000 Employee Stock Option (right to buy)
2024-02-13 Seehra Jasbir Buy 125 000 Employee Stock Option (right to buy)
2024-02-13 Regnante Keith Buy 40 000 Employee Stock Option (right to buy)
2024-02-13 Rovaldi Christopher Buy 150 000 Employee Stock Option (right to buy)
2024-02-13 Cooper Simon Peter Buy 40 000 Employee Stock Option (right to buy)
INSIDER POWER
67.74
Last 96 transactions
Buy: 1 546 013 | Sell: 365 314

Wolumen Korelacja

Długi: -0.03 (neutral)
Krótki: -0.40 (neutral)
Signal:(51.486) Neutral

Keros Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
PRAX0.919
CDNA0.904
HNNA0.894
RPAY0.889
TTEC0.888
EWTX0.883
SMSI0.882
SRAX0.879
ANNX0.876
LPCN0.874
10 Najbardziej negatywne korelacje
CNST-0.811
UNCY-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Keros Therapeutics Inc Korelacja - Waluta/Towar

The country flag 0.14
( neutral )
The country flag 0.02
( neutral )
The country flag 0.19
( neutral )
The country flag -0.01
( neutral )
The country flag 0.03
( neutral )
The country flag 0.03
( neutral )

Keros Therapeutics Inc Finanse

Annual 2023
Przychody: $151 000
Zysk brutto: $-664 000 (-439.74 %)
EPS: $-5.20
FY 2023
Przychody: $151 000
Zysk brutto: $-664 000 (-439.74 %)
EPS: $-5.20
FY 2022
Przychody: $0
Zysk brutto: $-1.62M (0.00 %)
EPS: $-4.15
FY 2021
Przychody: $20.10M
Zysk brutto: $0.00 (0.00 %)
EPS: $-2.52

Financial Reports:

No articles found.

Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej